Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism, a condition in which the thyroid gland produces too much of the hormone thyroxine. It is named after Robert J. Graves, an Irish physician who first described the disorder in 1835. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Symptoms of Graves’ disease can include weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland.
Graves’ disease is an autoimmune disorder in which the body’s immune system mistakenly attacks the thyroid gland. This causes the thyroid gland to produce too much of the hormone thyroxine. Too much thyroxine can lead to a number of symptoms, including weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Graves’ disease is the most common form of hyperthyroidism, and it is estimated to affect approximately 1 in 200 people.
The exact cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Studies have shown that people with Graves’ disease are more likely to have certain genetic variations, which may increase their risk of developing the disorder. Additionally, environmental factors such as stress, smoking, and certain medications may increase the risk of developing Graves’ disease.
Graves’ disease is typically diagnosed based on a physical examination and a review of the patient’s medical history. A doctor may also order blood tests to measure levels of thyroid hormones and antibodies associated with Graves’ disease. An imaging test such as an ultrasound or CT scan may be used to look for an enlarged thyroid gland.
Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. Medications such as antithyroid drugs, beta-blockers, and radioactive iodine can be used to reduce the production of thyroxine. Surgery to remove part or all of the thyroid gland is usually recommended for people with severe symptoms or those who do not respond to medications.
Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism and it is estimated to affect approximately 1 in 200 people. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. It is important for doctors to be aware of the signs and symptoms of Graves’ disease in order to properly diagnose and treat the disorder.
1.
Study finds 81% of cancer cures touted by TikTok videos are fake
2.
Telemedicine Not Reaching Rural Psychiatric Patients
3.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
4.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
5.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
1.
The Importance of Understanding Your D-Dimer Levels: A Comprehensive Guide
2.
Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
Updates on Standard V/S High Risk Myeloma Treatment
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation